Treatment of elderly cancer patients with chemotherapy

Cancer Investigation

Volumn 23, Issue 6, 2005, Pages 537-547

  Wasil, Tarun ^a,b   Lichtman, Stuart M ^a,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^c Memorial Sloan Kettering Cancer Center ^*

Author keywords

Age related physiology; Chemotherapy; Elderly patients

Indexed keywords

AMIFOSTINE; ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IRINOTECAN; METHOTREXATE; MONOCLONAL ANTIBODY; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; PREDNISONE; RITUXIMAB; SEROTONIN 3 ANTAGONIST; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; UNINDEXED DRUG; VINCRISTINE;

AGED; AGING; ANEMIA; BLEEDING; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; COLORECTAL CANCER; COMORBIDITY; CREATININE CLEARANCE; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM CANCER; ENZYME ACTIVITY; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL TOXICITY; GERIATRIC PATIENT; GLOMERULUS FILTRATION RATE; HEARING IMPAIRMENT; HEMATOPOIESIS; HIGH RISK PATIENT; HUMAN; HYPERTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; LUNG NON SMALL CELL CANCER; LUNG RESECTION; METASTASIS; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OSTEOPOROSIS; OVARY CANCER; PARTIAL MASTECTOMY; PATIENT MONITORING; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEINURIA; RASH; REVIEW; TREATMENT OUTCOME; VOMITING; WOUND HEALING IMPAIRMENT;

AGED; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS;

EID: 26844473321     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900500202770     Document Type: Review

References (157)

1. Yancik, R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 1997, 80, 1273-1283.
2. Edward, B.K.; Howe, H.L.; Ries, L.A.; Thun, M.J.; Rosenberg, H.M.; Yancik, R.; Wingo, P.A.; Jemal, A.; Feigal, E.G. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer 2002, 94, 2766-2792.
3. Lichtman, S.M.; Skirvin, J.A.; Vemulapalli, S. Pharmacology of antineoplastic agents in older cancer patients. Crit. Rev. Oncol./Hematol. 2003, 46, 101-114.
4. Repetto, L.; Biganzoli, L.; Koehne, C.H.; Luebbe, A.S.; Soubeyran, P.; Tjan-Heijan, V.C.; Aapro, M.S. Eortic cancer in the elderly task force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur. J. Cancer 2003, 39, 2264-2272.
5. Yee, K.W.; Pater, J.L.; Pho, L.; Zee, B.; Siu, L.L. Enrollment of older patients in cancer treatment trials in canada: why is age a barrier? J. Clin. Oncol. 2003, 21, 1618-1623.
6. John, V.; Mashru, S.; Lichtman, S. Pharmacological factors influencing anticancer drug selection in the elderly. Drugs Aging 2003, 20, 737-759.
7. Extermann, M.; Chen, H.; Cantor, A.B.; Corcoran, M.B.; Meyer, J.; Grendys, E.; Cavanaugh, D.; Antonek, S.; Camarata, A.; Haley, W.E.; Balducci, L. Predictors of tolerance to chemotherapy in older cancer patients. A prospective pilot study. Eur. J. Cancer 2002, 38, 1466-1473.
8. Extermann, M. Assessing elderly cancer patients. The SIOG task force on oncogeriatric assessment presents its findings to the experts. Cancer Futures 2003, 2, 155-157.
9. International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. The international non-Hodgkin's Lymphoma Prognostic Factors Project. N. Engl. J. Med. 1993, 329, 987-994.
10. Nixon, A.J.; Neuberg, D.; Rayes, D.F.; Gelman, R.; Connolly, J.L.; Schnitt, S.; Abner, A.; Recht, A.; Vicini, F.; Harris, J.R. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J. Clin. Oncol. 1994, 12, 888-894.
11. Kimmick, G.G.; Balducci, L. Breast cancer and aging. Clinical interactions. Hematol./Oncol. Clin. North Am. 2000, 14, 213-234.
12. Stone, R.M.; Berg, D.T.; George, S.L.; Dodge, R.K.; Paciucci, P.A.; Schulman, P.; Lee, E.J.; Moore, J.O.; Powell, B.L.; Schiffer, C.A. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and leukemia group B. N. Engl. J. Med. 1995, 332, 1671-1677.
13. Leith, C.P.; Kopecky, K.J.; Godwin, J.; McConnell, T.; Slovak, M.L.; Chen, I.M.; Head, D.R.; Appelbaum, F.R.; Willman, C.L. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997, 89, 3323-3329.
14. Preti, H.A.; Cabanillas, F.; Talpaz, M.; Tucker, S.L.; Seymour, J.F.; Kurzrock, R. Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann. Intern. Med. 1997, 127, 186-194.
15. Lipschitz, D.A. Aging of the hematopoietic system. In Principles of Geriatric Medicine and Gerontology; Hazzard, W.R., Bierman, E.L., Blass, J.P., Eds.; McGraw-Hill: New York, 1994; 733-739.
16. Dees, E.G.; O'Reilly, S.; Goodman, S.N.; Sartorius, S; Levine, M.A.; Jones, R.J.; Grochow, L.B.; Donehower, R.C.; Petting, J.H. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Investig. 2000, 18, 521-529.
17. Gomez, H.; Mas, L.; Casanova, L.; Pen, D.L.; Santillana, S.; Valdivia, S.; Otero, J.; Rodriguez, W.; Carracedo, C.; Vallejos, C. Elderly patients with aggressive non-Hodgkin's lymphoma treated with chop chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. J. Clin. Oncol. 1998, 16, 2352-2358.
18. Schild, S.E.; Stella, P.J.; Geyer, S.M.; Bonner, J.A.; McGinnis, W.L.; Mailliard, J.A.; Brindle, J.; Jatoi, A.; Jett, J.R. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J. Clin. Oncol. 2003, 21, 3201-3206.
19. Balducci, L.; Lyman, G.H. Patients aged > or = 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy. J. Clin. Oncol. 2001, 19, 1583-1585.
20. Balducci, L.; Yates, J. General guidelines for the management of older patients with cancer. Oncology (Huntingt.) 2000, 14, 221-227.
21. Balducci, L.; Repetto, L. Increased risk of myelotoxicity in elderly patients with non-Hodgkin lymphoma. Cancer 2004, 100, 6-11.
22. Morrison, V.A.; Weller, E.A.; Habermann, T.M.; Li, S.; Horning, S.J.; Fisher, R.I.; Peterson, B.A. Patterns of growth factor (gf) usage and febrile neutropenia (fn) among older patients (pts) with diffuse large B-cell lymphoma (dlbcl) treated with chop or r-chop: an intergroup experience (calgb 9793, ecog-swog 4494). Blood (ASH Abstracts) 2004, 104, 3309a.
23. Lyman, G.H.; Dale, D.C.; Crawford, J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J. Clin. Oncol. 2003, 21, 4524-4531.
24. Hutchins, L.F.; Unger, J.M.; Crowley, J.J.; Coltman, C.A., Jr.; Albain, K.S. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N. Engl. J. Med. 1999, 341, 2061-2067.
25. Baker, S.D.; Grochow, L.B. Pharmacology of cancer chemotherapy in the older person. Clin. Geriatr. Med. 1997, 13, 169-183.
26. DeMario, M.D.; Ratain, M.J. Oral chemotherapy, rationale and future directions. J. Clin. Oncol. 1998, 16, 2557-2567.
27. Richardson, J.L.; Shelton, D.R.; Krailo, M.; Levine, A.M. The effect of compliance with treatment on survival among patients with hematologic malignancies. J. Clin. Oncol. 1990, 8, 356-364.
28. Lebovits, A.H.; Strain, J.J.; Schleifer, S.J.; Tanaka, J.S.; Bhardwaj, S.; Messe, M.R. Patient noncompliance with self-administered chemotherapy. Cancer 1990, 65, 17-22.
29. Kastrissios, H.; Blaschke, T.F. Medication compliance as a feature in drug development. Annu. Rev. Pharmacol. Toxicol. 1997, 37, 451-475.
30. Urquhart, J. Patient compliance with crucial drug regimens: implications for prostate cancer. Eur. Urol. 1996, 29, 124-131.
31. Egorin, M.J. Cancer pharmacology in the elderly. Semin. Oncol. 1993, 20, 43-49.
32. Schrijvers, D.; Highley, M.; De Bruyn, E.; Van Oosterom, A.T.; Vermerken, J.B. Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Anti-Cancer Drugs 1999, 10, 147-153.
33. Evans, W.E.; McLeod, H.L. Pharmacogenomics-drug disposition, drug targets, and side effects. N. Engl. J. Med. 2003, 348, 538-549.
34. Flockhart, D. Cytochrome p450 drug interaction table. 2002, Available online at: http://medicine.iupui.edu/flockhart/ (accessed 26 July 2005).
35. Flockhart, D.A.; Tanus-Santos, J.E. Implications of cytochrome p450 interactions when prescribing medication for hypertension. Arch. Intern. Med. 2002, 162, 405-412.
36. Flockhart, D.A.; Rae, J.M. Cytochrome p450 3a pharmacogenetics: the road that needs traveled. Pharmacogenomics J. 2003, 3, 3-5.
37. Sotanieme, E.A.; Arranto, A.J.; Pelkonen, O.; Psanen, M. Age and cytochrome p450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin. Pharmacol. Ther. 1997, 61, 331-339.
38. Brenner, B.M.; Meyer, G.W.; Hostetter, T.H. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N. Engl. J. Med. 1982, 307, 652-659.
39. Swedko, P.J.; Clark, H.D.; Paramsothy, K.; Akbari, A. Serum creatinine is an inadequate screening test for renal failure in elderly patients. Arch. Intern. Med. 2003, 163, 356-360.
40. Cockcroft, D.W.; Gault, M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16, 31-41.
41. Jelliffe, R.W. Estimation of creatinine clearance when urine cannot be collected. Lancet 1971, 1, 975-976.
42. Marx, G.M.; Blake, G.M.; Galani, E.; Steer, C.B.; Harper, S.E.; Adamson, K.L.; Bailey, D.L.; Harper, P.C. Evaluation of the cockroft-gault, jelliffe and wright formulae in estimating renal function in elderly cancer patients. Ann. Oncol. 2004, 15, 291-295.
43. Kintzel, P.E.; Dorr, R.T. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat. Rev. 1995, 21, 33-64.
44. Charlson, M.E.; Pompei, P.; Ales, K.L.; MacKenzie, C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic. Dis. 1987, 40, 373-383.
45. Yancik, R.; Wesley, M.N.; Ries, L.A.; Havlik, R.J.; Long, S.; Edwards, B.K.; Yates, J.W. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer 1998, 82, 2123-2134.
46. Satariano, W.A.; Ragland, D.A. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann. Intern. Med. 1994, 720, 104-110.
47. Extermann, M.; Overcash, J.; Lyman, G.H.; Parr, J.; Balducci, L. Comorbidity and functional status are independent in older cancer patients. J. Clin. Oncol. 1998, 16, 1582-1587.
48. Rockwood, K.; Stadnyk, K.; MacKnight, C.; McDowell, I.; Hebert, R.; Hogan, D.B. A brief clinical instrument to classify frailty in elderly people. Lancet 1999, 353, 205-206.
49. Lunney, J.R.; Lynn, J.; Hogan, C. Profiles of older medicare decedents. J. Am. Geriatr. Soc. 2002, 50, 1108-1112.
50. Repetto, L.; Comandini, D.; Mammoliti, S. Life expectancy, comorbidity and quality of life: the treatment equation in the older cancer patients. Crit. Rev. Oncol./Hematol. 2001, 37, 147-152.
51. Fried, L.P.; Tangen, C.M.; Watson, J.; Newman, A.B.; Hirsch, C.; Gottdiener, J.; Seeman, T.; Tracy, R.; Kop, W.J.; Burke, G.; McBurnie, M.A. Frailty in older adults: evidence for a phenotype. J. Gerontol., Ser. A, Biol. Sci. Med. Sci. 2001, 56, M146-M156.
52. Balducci, L.; Stanta, G. Cancer in the frail patient. A coming epidemic. Hematol./Oncol. Clin. North Am. 2000, 14, 235-250.
53. Hamerman, D. Toward an understanding of frailty. Ann. Intern. Med. 1999, 130, 945-950.
54. Cohen, H.J.; Feussner, J.R.; Weinberger, M.; et al. A controlled trial of inpatient and outpatient geriatric evaluation and management. N. Engl. J. Med. 2002, 346, 905-912.
55. Ingram, S.S.; Seo, P.M.; Martell, R.E.; Clipp, E.C.; Doyle, M.E.; Montana, G.S.; Cohen, H.J. Comprehensive assessment of the elderly cancer patient: the feasibility of self-report methodology. J. Clin. Oncol. 2002, 20, 770-775.
56. Repetto, L.; Fratino, L.; Audisio, R.A.; Venturino, A.; Gianni, W.; Vercelli, M.; Parodi, S.; Dal Lago, D.; Gioia, F.; Monfardini, S.; Aapro, M.S.; Serraino, D.; Zagonel, V. Comprehensive geriatric assessment adds information to eastern cooperative oncology group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology study. J. Clin. Oncol. 2002, 20, 494-502.
57. Monfardini, S.; Ferrucci, L.; Fratino, L.; del Lungo, I.; Serraino, D.; Zagonel, V. Validation of a multidimensional evaluation scale for use in elderly cancer patients. Cancer 1996, 77, 395-401.
58. Bogg, D.R.; Patrene, K.D. Hematopoiesis and aging III: anemia and a blunted erythropoietic response to hemorrhage in aged mice. Am. J. Hematol. 1985, 19, 327-338.
59. Rothstein, G.; Christensen, R.D.; Nielsen, B.R. Kinetic evaluation of the pool sizes and proliferative response of neutrophils in bacterially challenged aging mice. Blood 1987, 70, 1836-1841.
60. Baraldi-Junkins, C.A.; Beck, A.C.; Rothstein, G. Hematopoiesis and cytokines. Relevance to cancer and aging. Hematol./Oncol. Clin. North Am. 2000, 14, pp. 45-61, viii.
61. Ania, B.J.; Suman, V.J.; Fairbanks, V.F.; Rademacher, D.M.; Melton, L.J., III. Incidence of anemia in older people: an epidemiologic study in a well defined population. J. Am. Geriatr. Soc. 1997, 45, 825-831.
62. Chaves, P.H.; Ashar, B.; Guralnik, J.M.; Fried, L.P. Looking at the relationship between hemoglobin concentration and prevalent mobility difficulty in older women. Should the criteria currently used to define anemia in older people be reevaluated? J. Am. Geriatr. Soc. 2002, 50, 1257-1264.
63. Ania, B.J.; Suman, V.J.; Fairbanks, V.F.; Melton, L.J., III. Prevalence of anemia in medical practice: community versus referral patients. Mayo Clin. Proc. 1994, 69, 730-735.
64. Crawford, J.; Dale, D.C.; Lyman, G.H. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004, 100, 228-237.
65. Schild, S.E.; Stella, P.J.; Geyer, S.M.; Bonner, J.A.; McGinnis, W.L.; Mailliard, J.A.; Brindle, J.; Jatoi, A.; Jett, J.R. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J. Clin. Oncol. 2003, 21, 3201-3206.
66. Argiris, A.; Li, Y.; Murphy, B.A.; Langer, C.J.; Forastiere, A.A. Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy. J. Clin. Oncol. 2004, 22, 262-268.
67. Lyman, G.H.; Delgado, D.J. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 2003, 98, 2402-2409.
68. Lyman, G.H.; Dale, D.C.; Crawford, J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J. Clin. Oncol. 2003, 21, 4524-4531.
69. Bonadonna, G.; Valagussa, P. Dose-response effect of adjuvant chemotherapy in breast cancer. N. Engl. J. Med. 1981, 304, 101-105.
70. Chrischilles, E.A.; Link, B.K.; Scott, S.D.; Delgado, D.J.; Fridman, M. Factors associated with early termination of CHOP therapy and the impact on survival among patients with chemosensitive intermediate-grade non-Hodgkin's lymphoma. Cancer Control 2003, 10, 396-403.
71. Dixon, D.O.; Neilan, B.; Jones, S.; Lipschitz, D.A.; Miller, T.P.; Grozea, P.N.; Wilson, H.E. Effect of age on therapeutic outcome in advanced diffuse histocytic lymphoma: the Southwest Oncology Group experience. J. Clin. Oncol. 1986, 4, 295-305.
72. Muss, H.; Woolf, S.; Berry, D.; Weiss, R.; Budman, D.; Wood, W.; Henderson, C.; Hudis, C.; Norton, L. Older women with node positive (n+) breast cancer (be) get similar benefits from adjuvant chemotherapy (adj) as younger patients (pts): the cancer and leukemia group B (calgb) experience. Proc. Ann. Meet. Am. Soc. Clin. Oncol. 2003, 22, 11a.
73. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998, 552, 930-942.
74. Hurria, A.; Leung, D.; Trainer, K.; Borgen, P.; Norton, L.; Hudis, C. Factors influencing treatment patterns of breast cancer patients age 75 and older. Crit. Rev. Oncol./Hematol. 2003, 46, 121-126.
75. Hughes, K.S.; Schnaper, L.; Berry, D.; et al. Comparison of lumpectomy plus tamoxifen with and without radiotherapy (rt) in women 70 years of age or older who have clinical stage I, estrogen receptor positive (er+) breast carcinoma. Proc. Ann. Meet. Am. Soc. Clin. Oncol. 2001, 20, 93a.
76. Budman, D.R.; Berry, D.A.; Cirrincione, C.T.; Henderson, I.C.; Wood, W.C.; Weiss, R.B.; Ferree, C.R.; Muss, H.B.; Green, M.R.; Norton, L.; Frei, E. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The cancer and leukemia group B. J. Natl. Cancer Inst. 1998, 90, 1205-1211.
77. Crivellari, D.; Bonetti, M.; Castiglione-Gertsch, M.; Gelber, R.D.; Rudenstam, C.M.; Thurlimann, B.; Price, K.N.; Coates, A.S.; Hurny, C.; Bernhard, J.; Lindtner, J.; Collins, J.; Senn, H.J.; Cavalli, F.; Forbes, J.; Gudgeon, A.; Simoncini, E.; Cortes-Funes, H.; Veronesi, A.; Fey, M.; Goldhirsch, A. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group trial VII. J. Clin. Oncol. 2000, 18, 1412-1422.
78. Lichtman, S.M.; Zaheer, W.; Gal, D.; Lovecchio, J.; DeMarco, L.C.; Schulman, P.; Budman, D.R.; Taibbi, R.; Fenton, C.; Vinciguerra, V. No increased risk of taxol toxicity in older patients. J. Am. Geriatr. Soc. 1996, 44, 472-474.
79. Del Mastro, L.; Perrone, F.; Repetto, L.; Manzione, L.; Zagonel, V.; Fratino, L.; Marenco, D.; Venturini, M.; Maggi, E.; Bighin, C.; Catzeddu, T.; Venturino, A.; Rosso, R. Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGER). Ann. Oncol. 2005, 16, 253-258.
80. Citron, M.L.; Berry, D.A.; Cirrincione, C.; Hudis, C.; Winer, E.P.; Gradishar, W.J.; Davidson, N.B.; Martino, S.; Livingston, R.; Ingle, J.N.; Perez, E.A.; Carpenter, J.; Hurd, D.; Holland, J.F.; Smith, B.L.; Sartor, C.I.; Leung, E.H.; Abrams, J.; Schilsky, R.L.; Muss, H.B.; Norton, L. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial c9741/cancer and leukemia group B trial 9741. J. Clin. Oncol. 2003, 21, 1431-1439.
81. Buzdar, A.U. 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer - efficacy overview. J. Steroid Biochem. Mol. Biol. 2003, 86, 399-403.
82. Klijn, J.; for the ATAC Trialists' Group. The ATAC (anastrozole, tamoxifen, alone or in combination) trial. An efficacy update, focusing on breast cancer (be) events, based on a median follow-up of 47 months. Proc. Ann. Meet. Am. Soc. Clin. Oncol. 2003, 22, 338a.
83. Howell, A.; Cuzick, J.; Baum, M.; Buzdar, A.; Dowsett, M.; Forbes, J.F.; Hoctin-Boes, G.; Houghton, J.; Locker, G.Y.; Tobias, J.S. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365, 60-62.
84. Goss, P.E.; Ingle, J.N.; Martino, S.; Robert, N.J.; Muss, H.B.; Piccart, M.J.; Castiglione, M.; Tu, D.; Shepherd, L.E.; Pritchard, K.I.; Livingston, R.B.; Davidson, N.B.; Norton, L.; Perez, E.A.; Abrams, J.S.; Therasse, P.; Palmer, M.J.; Pater, J.L. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 2003, 349, 1793-1802.
85. Nabholtz, J.M.; Buzdar, A.; Pollak, M.; Harwin, W.; Burton, G.; Mangalik, A.; Steinberg, M.; Webster, A.; von Euler, M. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J. Clin. Oncol. 2000, 18, 3758-3767.
86. Mouridsen, H.; Gershanovich, M.; Sun, Y.; Perez-Carrion, R.; Boni, C.; Monnier, A.; Apffelstaedt, J.; Smith, R.; Sleeboom, H.P.; Janicke, F.; Pluzanska, A.; Dank, M.; Becquart, D.; Bapsy, P.P.; Salminen, E.; Snyder, R.; Lassus, M.; Verbeek, J.A.; Staffler, B.; Chaudri-Ross, H.A.; Dugan, M. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer, results of a phase III study of the International Letrozole Breast Cancer Group. J. Clin. Oncol. 2001, 19, 2596-2606.
87. Vogel, C.; Cobleigh, M.A.; Tripathy, D.; Gutheil, J.C.; Harris, L.N.; Fehrenbacher, L.; Slamon, D.J.; Murphy, M.; Novotny, W.F.; Burchmore, M.; Shak, S.; Stewart, S.J. First-line, single-agent herceptin(trastuzumab) in metastatic breast cancer; a preliminary report. Eur. J. Cancer 2001, 37 (Suppl. 1), S25-S29.
88. Slamon, D.J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M.; Baselga, J.; Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344, 783-792.
89. Burstein, H.; Kuter, I.; Campos, S.; Gelman, R.; Tribou, L.; Parker, L.; Manola, J.; Younger, J.; Matulonis, U.; Bunnell, C.; Partridge, A.; Richardson, P.; Clarke, K.; Shulman, L.; Winer, E. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2001, 19, 2722-2730.
90. Sledge, G.W., Jr. Gemcitabine combined with paclitaxel or paclitaxel/trastuzumab in metastatic breast cancer. Semin. Oncol. 2003, 30, 19-21.
91. O'Shaughnessy, J.A. Potential of capecitabine as first-line therapy for metastatic breast cancer: dosing recommendations in patients with diminished renal function. Ann. Oncol. 2002, 13, 983.
92. O'Shaughnessy, J.A.; Blum, J.; Moiseyenko, V.; Jones, S.E.; Miles, D.; Bell, D.; Rosso, R.; Mauriac, L.; Osterwalder, B.; Burger, H.U.; Laws, S. Randomized, open-label, phase II trial of oral capecitabine (xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann. Oncol. 2001, 12, 1247-1254.
93. Seidman, A.D.; Berry, D.; Cirrincione, C.; Howell, A.; Cuzick, J.; Baum, M.; Buzdar, A.; Dowsett, M.; Forbes, J.F.; Hoctin-Boes, G.; Houghton, J.; Locker, G.Y.; Tobias, J.S. Calgb 9840: phase III study of weekly (w) paclitaxel (p) vita 1-hour(h) infusion versus standard (s) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (t) for HER2 positive MBC and randomized for t in HER2 normal MBC. J. Clin. Oncol. (Meeting Abstracts) 2004, 22, 512.
94. Perez, E.A.; Vogel, C.L.; Irwin, D.H.; Kirshner, J.J.; Patel, R. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J. Clin. Oncol. 2001, 19, 4216-4223.
95. Sundararajan, V.; Grann, V.R.; Jacobson, J.S.; Ahsan, H.; Neugut, A.I. Variations in the use of adjuvant chemotherapy for node-positive colon cancer in the elderly, a population-based study. Cancer J. 2001, 7, 213-218.
96. Sundararajan, V.; Mitra, N.; Jacobson, J.S.; Grann, V.R.; Heitjan, D.F.; Neugut, A.I. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann. Intern. Med. 2002, 136, 349-357.
97. Neugut, A.I.; Fleischauer, A.T.; Sundararajan, V.; Mitra, N.; Heitjan, D.F.; Jacobson, J.S.; Grann, V.R. Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly, a population-based study. J. Clin. Oncol. 2002, 20, 2643-2650.
98. Sargen, D.J.; Goldberg, R.M.; Jacobson, S.D.; et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N. Engl. J. Med. 2001, 345, 1091-1097.
99. Stein, B.N.; Petrelli, N.J.; Douglas, H.O.; Driscoll, D.L.; Arcangeli, G.; Meropol, N.J. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 1995, 75, 11-17.
100. Chiara, S.; Nobile, M.T.; Vincenti, M.; Lionetto, R.; Gozza, A.; Barzacchi, M.C.; Sanguineti, O.; Repetto, L.; Rosso, R. Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy. Cancer Chemother. Pharmacol. 1998, 42, 336-340.
101. de Gramont, A.; Banzi, M.; Navarro, M.; et al. Oxaliplatin/5-fu/lv in adjuvant colon cancer: results of the International Randomized MOSAIC trial. Proc. Ann. Meet. Am. Assoc. Cancer Res. 2003, 22, 1015a.
102. Tabah-Fisch, I.; Maindrault-Goebel, F.; Benavides, M.; et al. Oxaliplatin/5fu/lv is feasible, safe and active in elderly colorectal cancer (CRC) patients. Proc. Ann. Meet. Am. Soc. Clin. Oncol. 2002, 21, 556a.
103. Carreca, I.; Cornelia, P.; Maiorino, L.; et al. Oral capecitabine plus oxaliplatin (xelox regimen) in elderly patients with advanced colorectal carcinoma (ACC). Southern Italy Cooperative Oncology Group (SICOG 0108) phase II study. Proc. Ann. Meet. Am. Soc. Clin. Oncol. 2003, 22, 2939a.
104. Aparicio, T.; Desrame, J.; Lecomte, T.; Mitry, E.; Belloc, J.; Etienney, I.; Montembault, S.; Vayre, L.; Locher, C.; Ezenfis, J.; Artru, P.; Mabro, M.; Dominguez, S. Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. Br. J. Cancer 2003, 89, 1439-1444.
105. Douillard, J.Y.; Sobrero, A.; Carnaghi, C.; Cornella, P.; Diaz-Rubio E.; Santoro, A.; Van Cutsem, E. Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy. Ann. Oncol. 2003, 14 (Suppl. 2), ii7-ii12.
106. Tournigand, C.; Andre, T.; Achille, E.; Lledo, G.; Flesh, M.; Mery-Mignard, D.; Quinaux, E.; Couteau, C.; Buyse, M.; Ganem, G.; Landi, B.; Colin, P.; Louvet, C.; de Gramont, A. Folfiri followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. 2004, 22, 229-237.
107. Goldberg, R.M.; Sargent, D.J.; Morton, R.F.; Fuchs, C.S.; Ramanathan, R.K.; Williamson, S.K.; Findlay, B.P.; Pilot, H.C.; Alberts, S.R. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 2004, 22, 23-30.
108. Takimoto, C.H.; Remick, S.C.; Sharma, S.; Mani, S.; Ramanathan, R.K.; Doroshow, J.H.; Hamilton, A.; Mulkerin, D.; Graham, M.; Lockwood, G.F.; Ivy, P.; Egorin, M.; Greenslade, D.; Goetz, A.; Grem, J.L. Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group. Semin. Oncol. 2003, 30, 20-25.
109. Saltz, L.B.; Cox, J.V.; Blanke, C.; Rosen, L.S.; Fehrenbacher, L.; Moore, M.J.; Maroun, J.A.; Ackland, S.P.; Locker, P.K.; Pirotta, N.; Elfring, G.L.; Miller, L.L. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group. N. Engl. J. Med. 2000, 343, 905-914.
110. Venook, A.P.; Enders Klein, C.; Fleming, G.; Mollis, D.; Leichman, C.G.; Hohl, R.; Byrd, J.; Budman, D.; Villalona, M.; Marshall, J.; Rosner, G.L.; Ramirez, J.; Kastrissios, H.; Ratain, M.J. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann. Oncol. 2003, 14, 1783-1790.
111. Rothenberg, M.L.; Berlin, J.D. Therapeutic strategies for metastatic colorectal cancer: simultaneous, sequential, or specific? J. Clin. Oncol. 2003, 27, 3716-3717.
112. Rothenberg, M.L.; Oza, A.M.; Bigelow, R.H.; Berlin, J.D.; Marshall, J.L.; Ramanathan, R.K.; Hart, L.L.; Gupta, S.; Garay, C.A.; Burger, B.G.; Le Bail, N.; Haller, D.G. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J. Clin. Oncol. 2003, 21, 2059-2069.
113. Hurwitz, H.; Fehrenbacher, L.; Cartwright, T.; Hainsworth, J.; et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc. Ann. Meet. Am. Soc. Clin. Oncol. 2003, 22, 3646a.
114. Hoff, P.M.; Ansari, R.; Batist, G.; Cox, J.; Kocha, W.; Kuperminc, M.; Maroun, J.; Walde, D.; Weaver, C.; Harrison, E.; Burger, H.U.; Osterwalder, B.; Wong, A.O.; Wong, R. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J. Clin. Oncol. 2001, 19, 2282-2292.
115. Van Cutsem, E.; Twelves, C.; Tabemero, J.; et al. Xelox: mature results of a multinational, phase II trial of capecitabine plus oxaliplatin, an effective first-line option for patients with metastatic colorectal cancer. Proc. Ann. Meet. Am. Assoc. Cancer Res. 2003, 22, 1023a.
116. Bollina, R.; Beretta, G.; Toniolo, D.; Cozzi, C.; et al. Capecitabine (c) and irinotecan (i) (CAPIRI): a good combination in elderly patients (pts) with advanced colorectal cancer (ACRC) as first line chemotherapy (ct). Preliminary results of a phase II trial. Proc. Ann. Meet. Am. Soc. Clin. Oncol. 2003, 22, 1332a.
117. Szatrowski, T.P. Correspondence from Roche Laboratories, Inc., 2000.
118. Cunningham, D.; Humblet, Y.; Siena, S.; et al. Cetuximab (c225) alone or in combination with irinotecan (cpt-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Proc. Ann. Meet. Am. Soc. Clin. Oncol. 2003, 22, 1012a.
119. Salomon, D.S.; Brandt, R.; Ciardiello, F.; Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol./Hematol. 1995, 19, 183-232.
120. Messa, C.; Russo, F.; Caruso, M.G.; Di Leo, A. EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncol. 1998, 37, 285-289.
121. Mayer, A.; Takimoto, M.; Fritz, E.; Schellander, G.; Kofler, K.; Ludwig, H. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and MDR gene expression in colorectal cancer. Cancer 1993, 71, 2454-2460.
122. Salt, L.B.; Meropol, N.J.; Loehrer, P.J., Sr.; Needle, M.N.; Kopit, J.; Mayer, R.J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 2004, 22, 1201-1208.
123. Fisher, R.I.; Gaynor, E.R.; Dahlberg, S.; Oken, M.M.; Grogen, T.M.; Mize, E.M.; Click, J.H.; Coltman, C.A.J.; Miller, T.P. Comparison of a standard regimen (chop) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N. Engl. J. Med. 1993, 328, 1002-1006.
124. Kouroukis, C.T.; Browman, G.P.; Esmail, R.; Meyer, R.M. Chemotherapy for older patients with newly diagnosed, advanced-stage, aggressive-histology non-Hodgkin lymphoma: a systematic review. Ann. Intern. Med. 2002, 136, 136-143.
125. Lichtman, S.M. Aggressive lymphoma in the elderly. Crit. Rev. Oncol./Hematol. 2000, 33, 119-128.
126. Riechmann, L.; Clark, M.; Waldmann, H.; Winter, G. Reshaping human antibodies for therapy. Nature 1988, 332, 323-327.
127. McLaughlin, P.; Grillo-Lopez, A.J.; Link, B.K.; Levy, R.; Czuczman, M.S.; Williams, M.E.; Heyman, M.R.; Bence-Bruckler, I.; White, C.A.; Cabanillas, F.; Jain, V.; Ho, A.D.; Lister, J.; Wey, K.; Shen, D.; Dallaire, B.K. Rituximab chimeric anti-cd20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 1998, 16, 2825-2833.
128. Coiffier, B.; Lepage, E.; Briere, J.; Herbrecht, R.; Tilly, H.; Bouabdallah, R.; Morel, P.; Van Den Neste, E.; Salles, G.; Gaulard, P.; Reyes, F.; Lederlin, P.; Gisselbrecht, C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 2002, 346, 235-242.
129. Habermann, T.; Weller, E.; Morrison, V.A.; Cassileth, P.A.; Cohn, J.; Dakhil, S.; Gascoyne, R.D.; Woda, B.; Fisher, R.; Peterson, B.A.; Horning, S.J. Rituximab-CHOP versus CHOP with or without maintenance rituximab in patients 60 years of age or older with diffuse large B-cell lymphoma (DLBCL): an update. Blood (ASH Abstracts) 2004, 104, 127a.
130. Pfreundschul, M.; Truemper, L.; Kloes, M.; et al. 2-Weekly vs. 3-weekly CHOP with and without etoposide for patients >60 years of age with aggressive non-Hodgkin's lymphoma (NHL): results of the completed NHL-b-2 trial of the DSHNHL. Blood 2002, 99 (Suppl. 1), 3060a.
131. Sundararajan, V.; Hershman, D.; Grann, V.R.; Jacobson, J.S.; Neugut, A.I. Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study. J. Clin. Oncol. 2002, 20, 173-178.
132. McGuire, W.P.; Hoskins, W.J.; Brady, M.F.; Kucera, P.R.; Partridge, E.E.; Look, K.Y.; Clarke-Pearson, D.L.; Davidson, M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 1996, 334, 1-6.
133. Neijt, J.P.; Engelholm, S.A.; Tuxen, M.K.; Sorensen, P.G.; Hansen, M.; Sessa, C.; de Swart, C.A.; Hirsch, F.R.; Lund, B.; van Houwelingen, H.C. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J. Clin. Oncol. 2000, 18, 3084-3092.
134. Langer, C.J.; Manola, J.; Bernard, P.; Kugler, J.W.; Bonomi, P.; Cella, D.; Johnson, D.H. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J. Natl. Cancer Inst. 2002, 94, 173-181.
135. Lichtman, S.M.; Buchholtz, M.; Marino, J.; Schulman, P.; Allen, S.L.; Weiselberg, L.; Budman, D.; DeMarco, L.; Schuster, M.; Lovecchio, J.; et al. Use of cisplatin for elderly patients. Age Ageing 1992, 27, 202-204.
136. Calvert, A.H.; Newell, D.R.; Gumbrell, L.A.; S, O.R.; Burnell, M.; Boxall, F.E.; Siddik, Z.H.; Judson, I.R.; Gore, M.E.; Wiltshaw, E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol. 1989, 7, 1748-1756.
137. Ozols, R.F. Optimum chemotherapy for ovarian cancer. Int. J. Gynecol. Cancer 2000, 10, 33-37.
138. Gronlund, B.; Hogdall, C.; Hansen, H.H.; Engelholm, S.A. Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma. Cancer 2002, 94, 1961-1967.
139. Dizon, D.S.; Hensley, M.L.; Poynor, E.A.; et al. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. J. Clin. Oncol. 2002, 20, 1238-1247.
140. Ozols, R.F. Recurrent ovarian cancer: evidence-based treatment. J. Clin. Oncol. 2002, 20, 1161-1163.
141. Hainsworth, J.D.; Burris, H.A., III; Litchy, S.; Morrissey, L.H.; Barton, J.H.; Bradof, I.E.; Greco, F.A. Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network phase II trial. Cancer 2000, 89, 328-333.
142. Perez, E.A.; Vogel, C.L.; Irwin, D.H.; Kirshner, J.J.; Patel, R. Weekly paclitaxel in women age 65 and above with metastatic breast cancer. Breast Cancer Res. Treat. 2002, 73, 85-88.
143. Homesley, H.D.; Hall, D.J.; Martin, D.A.; Lewandowski, G.S.; Vaccarello, L.; Nahhas, W.A.; Suggs, C.L.; Penley, R.G. A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gynecol. Oncol. 2001, 83, 394-399.
144. Armstrong, D.K. Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity. Oncologist 2004, 9, 33-42.
145. Seymour, M.T.; Mansi, J.L.; Gallagher, C.J.; Gore, M.E.; Harper, P.G.; Evans, T.R.; Edmonds, P.M.; Slevin, M.L. Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease. Br. J. Cancer 1994, 69, 191-195.
146. Rocha Lima, C.; Herndon, J.; Kosty, M.; Clamon, G.; Green, M. Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the cancer and leukemia group B. Cancer 2002, 94, 181-187.
147. Hensing, T.A.; Peterman, A.H.; Schell, M.J.; Lee, J.H.; Socinski, M.A. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer 2003, 98, 779-788.
148. Sequist, L.V.; Lynch, T.J. Aggressive treatment for the fit elderly with non-small-cell lung cancer? Yes! J. Clin. Oncol. 2003, 3186-3188.
149. Gridelli, C.; Perrone, F.; Gallo, C.; De Marinis, F.; Ianniello, G.; Cigolari, S.; Cariello, S.; Di Costanzo, F.; M, D.A.; Rossi, A.; Migliorino, R.; Bartolucci, R.; Bianco, A.R.; Pergola, M.; Monfardini, S. Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study. Eur. J. Cancer 1997, 33, 392-397.
150. Gridelli, C.; Perrone, F.; Gallo, C.; Cigolari, S.; Rossi, A.; Piantedosi, F.; Barbera, S.; Ferrau, F.; Piazza, E.; Rosetti, F.; Clerici, M.; Bertetto, O.; Robbiati, S.F.; Frontini, L.; Sacco, C.; Castiglione, F.; Favaretto, A.; Novello, S.; Migliorino, M.R.; Gasparini, G.; Galetta, D.; Iaffaioli, R.V.; Gebbia, V. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (Miles) phase III randomized trial. J. Natl. Cancer Inst. 2003, 95, 362-372.
151. Lilenbaum, R. Management of advanced non-small-cell lung cancer in patients with a performance status of 2. Clin. Lung Cancer 2004, 5, 209-213.
152. Lilenbaum, R. Management of advanced non-small-cell lung cancer in elderly populations. Clin. Lung Cancer 2003, 5, 169-173.
153. Schiller, J.H.; Harrington, D.; Belani, C.P.; Langer, C.; Sandler, A.; Krook, J.; Zhu, J.; Johnson, D.H. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 2002, 346, 92-98.
154. Shepherd, F.A.; Dancey, J.; Ramlau, R.; Mattson, K.; Gralla, R.; O'Rourke, M.; Levitan, N.; Gressot, L.; Vincent, M.; Burkes, R.; Coughlin, S.; Kim, Y.; Berille, J. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 2000, 18, 2095-2103.
155. Johnson, D.H.; Arteaga, C.L. Gefitinib in recurrent non-small-cell lung cancer: an ideal trial? J. Clin. Oncol. 2003, 21, 2227-2229.
156. Cappuzzo, F.; Gregore, V.; Rossi, E.; Cancellieri, A.; Magrini, E.; Paties, C.T.; Ceresoli, G.; Lombardo, L.; Bartolini, S.; Calandri, C.; De Rosa, M.; Villa, E.; Crino, L. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J. Clin. Oncol. 2003, 21, 2658-2663.
157. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N. Engl. J. Med. 2004, 350, 351-360.